UVA launches human testing of lung transplant drug

Posted by:

In the culmination of decades of research at the University of Virginia Health System, doctors have begun human testing of a drug they hope will one day save many lives among lung transplant recipients.

The drug, regadenoson, is already commonly used to image cardiac patients’ hearts. But the UVA research suggests it could be put to another, lifesaving purpose: battling ischemia reperfusion injury, in which tissue is damaged by the restoration of blood flow after it has been cut off.

The principal investigator of UVA’s trial, Dr. Christine L. Lau, called ischemia reperfusion injury the “Achilles’ heel of lung transplant.”

“Ischemia reperfusion injury directly correlates to the development of chronic rejection, which is the reason why five-year survival in lung transplant recipients is only about 50 percent,” said Lau, a surgeon. “Yet there really are almost no [other] clinical trials in lung transplant. This is our best hope.”

Continue reading at https://news.virginia.edu/content/after-decades-work-uva-launches-human-tests-lung-transplant-drug

0

About the Author:

Corey joins The Alliance with more than ten years of experience in corporate and non-profit fields, having worked in Communications for The Walt Disney Company and most recently, Public Relations for TransLife, the OPO serving Central Florida. He has also been an active board member of Donate Life Florida, serving as state team leader for the Driver License Outreach taskforce. Corey holds a Bachelor of Arts in Communication and Information Sciences from The University of Alabama. In his spare time, he is an avid music and theater enthusiast, enjoys traveling, Crimson Tide Football and serving on the board for several local charities in the Orlando area.
  Related Posts

Add a Comment